Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

relapsed multiple myeloma

Home/Tag:relapsed multiple myeloma
19 09, 2014

Relapsed/refractory patients face difficult choices

Tags: , , , , , , , |21 Comments

I reported back Wednesday afternoon after meeting with my myeloma specialist, Dr. Roy, at Mayo Clinic.  The contrast between Dr. Roy's slow and steady incremental therapy approach, and the "hit the myeloma hard" Total Therapy approach preferred by Dr. Tricot on Wednesday night's broadcast couldn't have been more stark. Dr. Tricot enthusiastically stated that he

1 08, 2014

BREAKING NEWS: For many, more Kyprolis is better

Tags: , , , , |6 Comments

A Stage 2 clinical trial has confirmed what many myeloma specialists already knew: increasing Kyprolis dosing improves patient outcomes. Here are the results, published in BLOOD and run in Hem Onc Today: Higher carfilzomib dose induced durable response in multiple myeloma A higher dose of carfilzomib induced a high overall response rate and “a remarkable

8 07, 2014

Two easy ways to increase your myeloma IQ

Tags: , , , |4 Comments

By now I shouldn't need to convince you that patient education is the cornerstone of living better and longer with multiple myeloma.  Access to audio and video interviews with leading myeloma specialists helps make it easy. Several times a month the clinical trial search engine, TrialX, sponsors Cure Talk broadcasts focusing on multiple myeloma.   I'm

1 06, 2014

All relapsed/refractory patients not created equal

Tags: , , , |5 Comments

As I mentioned earlier this week, there isn't much myeloma related activity at the American Society of Clinical Oncology (ASCO) until Monday.  That gives us a chance to review a couple of important things to look for when comparing one experimental therapy to another. Let's start with relapsed/refractory.  Someone who relapses isn't necessarily refractory (resistant)

9 12, 2013

Welcome to the wild wild west of myeloma therapy!

Tags: , , , , |10 Comments

Covering technical, four hour events like Friday’s pre-ASH symposium can be challenging; even grueling.  My peripheral neuropathy and back pain makes it hard to sit still and type on the fly.  And this year I'm trying to tweet simultaneously while blogging. It’s hard for a symptomatic myeloma survivor to cover as much material as a

4 10, 2013

The mystery of cause and effect: What triggers a relapse?

Tags: , , , , |12 Comments

Something remarkable happened yesterday in response to my monthly column in the Myeloma Beacon.  Debbie Berns, leader of the International Myeloma Foundation's (IMF) awesome phone counseling team, took time out of her busy day to email me some important information relating to my relapse. I was working on what I had planned to be today's

22 04, 2013

Everything that you ever wanted to know about myeloma but were afraid to ask!

Tags: , , |2 Comments

When I was first diagnosed, I remember scouring the web for information.  I was eventually able to piece things together in drips and drabs.  But my quest was emotionally draining.  Too many promising reports sites turned-out to be dead ends.  I have tried to remedy that a bit by summarizing the things I think are

17 01, 2013

Free myeloma event January 28th at Moffitt

Tags: , , , , , , |0 Comments

Yesterday I wrote about a conversations I had with tough, never-say-die and long-lived multiple myeloma survivor, Dr. Arnold Goodman.  The meeting meant so much to me I practically gushed with admiration over Arnie's ability to overcome the difficult hand he has been dealt.  But I don't want to forget the reason we were there in

1 04, 2012

Spot-on continuing ed program covers all of the myeloma therapy bases…

Tags: , , |0 Comments

Wow!  This continuing ed course for medical oncologists and hematologists is really interesting! The Challenge of Relapsed and/or Refractory Multiple Myeloma Complete with an accompanying power point presentation and lots of charts and slides, this Medscape Education program is both comprehensive and up-to-date, including reviews of carfilzomib, pomalidomide and elotuzumab. It may be a bit

13 11, 2011

TIP: Understanding the difference between “time to disease progression” and “median life expectancy”

Tags: , , , |4 Comments

Time to disease progression and median life expectancy are the two primary measurements used to evaluate how well a new anti-myeloma therapy is working. Time to disease progression refers to how long it takes for a patient's multiple myeloma to return after they start using a therapy. Median life expectancy measures how long a patient